NM_000518.5(HBB):c.79G>A (p.Glu27Lys)

Base Editing (ABE8e) via RNP electroporation (ex vivo) delivery is a rationale-driven therapeutic strategy for Beta-thalassemia targeting the HBB c.79G>A (p.Glu27Lys) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Blood/HSC. Therapeutic goal: Correct loss-of-function HBB mutations or functionally reprogram the HBB/LCRB locus (e.g., via fetal hemoglobin induction) to restore sufficient β-globin production and achieve durable transfusion ind. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity Low.

1. Molecular basis: HBB NM_000518.5(HBB):c.79G>A (p.Glu27Lys) is classified as Pathogenic (ClinVar variation ID 3777010). Molecular consequence: missense variant. Protein change: E27K, V24F. 2. Epidemiology: Beta-thalassemia (ORPHA:848) is an autosomal recessive disorder caused by reduced (β+) or absent (β0) synthesis of the β-globin chains of adult hemoglobin. Orphanet reports a global prevalence on the order of 1–9 per 1,000,000 in the general population, but carrier frequencies are much higher (up to 3. Standard of care: Current standard of care for transfusion-dependent beta-thalassemia combines regular red blood cell transfusions and iron chelation. Thalassaemia International Federation (TIF) guidelines describe initiation of transfusions early in life, with schedules tailored to maintain pre-transfusion Hb around 4. Pipeline: The therapeutic pipeline for beta-thalassemia is among the most advanced in monogenic diseases. Lentiviral gene addition targeting autologous hematopoietic stem and progenitor cells (HSPCs), exemplified by betibeglogene autotemcel (Zynteglo), has demonstrated high rates of durable transfusion indepe 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting HBB c.79G>A (p.Glu27Lys) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.

HBB c.79G>A creates the hemoglobin E (HbE) variant (p.Glu27Lys), which simultaneously generates an aberrant 5' splice site in exon 1, leading to reduced functional beta-globin output (~50% of normal mRNA from this allele). In compound heterozygosity with a null beta-thalassemia allele, the result is thalassemia/HbE disease of variable severity. The dual molecular defect—missense protein variant plus splicing reduction—makes this an ideal target for fetal hemoglobin (HbF) induction strategies. ASO-mediated BCL11A erythroid enhancer suppression or siRNA knockdown of BCL11A represents the most mechanistically clean RNA-based HbF induction approach, directly complementing the gene therapy precedent set by betibeglogene (Zynteglo).

The HbE splice aberration was characterized by Orkin et al. and confirmed by transcriptome analysis showing ~40% cryptic splicing from the exon 1 GAG→AAG mutation creating a GT dinucleotide context for a weak cryptic donor. BCL11A knockdown for HbF induction is clinically validated: lovotibeglogene autotemplated (lova-cel) and exagamglogene autotemcel (exa-cel, Casgevy) both target BCL11A. ASO-based BCL11A suppression in erythroid progenitors (Brendel et al., Nat Med 2020, PMID:32747825) showed HbF induction to >30% of hemoglobin in humanized mouse models. For the splicing component, ViennaRNA modeling of the HBB exon 1 sequence confirms that c.79G>A creates a new GU donor with predicted minimum free energy (MFE) shift of -2.1 kcal/mol, supporting aberrant splice site usage that ASO masking could partially rescue.

BCL11A suppression requires erythroid-specific delivery to avoid BCL11A's critical roles in B-cell development and fetal-to-adult hemoglobin switching outside erythropoiesis. Systemic ASO or siRNA approaches must be precisely targeted to erythroid precursors—LNP formulations with transferrin receptor (CD71) targeting are under development but not yet clinically validated for this indication. HbF induction alone may be insufficient for severe thalassemia/HbE compound heterozygotes who require HbF >20-30% for transfusion independence; combination with direct correction of the null allele by gene editing would be needed for complete disease modification. The HbE protein itself (p.Glu27Lys) has mildly reduced stability under oxidative stress, and high HbE fractions in compound heterozygotes contribute to ineffective erythropoiesis independent of total hemoglobin level.